Q Biomed Stock Price, News & Analysis

Q BioMed Inc. has announced a strengthening of its IP portfolio with a new patent granted for its liver cancer drug candidate, Uttroside B, in the US, as well as a notice of allowance in Europe, adding to existing patents in Korea, Canada, and Japan. This candidate has received Orphan Drug designation from the FDA and shows promising results in pre-clinical tests. With liver cancer cases rising, there is significant demand for effective treatments. CEO Denis Corin emphasized exploring strategic options to enhance shareholder value despite challenging market conditions. Q BioMed also holds a $3.5M stake in Mannin Research and anticipates this value could rise due to ongoing trials and funding, potentially exceeding $100M. The company is committed to recognizing its inherent asset value despite stock performance issues, influenced by macroeconomic factors.

Q BioMed Inc. announced promising results regarding its chemotherapeutic agent, Uttroside B, which has received a notice of allowance for a patent from the United States Patent Office. This follows existing patents in Canada, Korea, and Japan. The compound, which has shown ten times the cytotoxicity against hepatocellular carcinoma (HCC) compared to existing therapies, has also been designated as an Orphan Drug by the FDA. With an increasing demand for effective liver cancer treatments and a projected market growth of 29.4% over the next decade, Uttroside B presents significant opportunities for Q BioMed in the healthcare sector.

Q BioMed Inc. (QBIO) has converted its long-term royalty agreement into a 15% equity stake in Mannin Research Inc. (MRI), valuing MRI at CAD$30 million. This conversion grants QBIO a $20 million royalty on future net sales. The investment is expected to grow significantly due to upcoming commercialization agreements and clinical milestones. With MRI's pipeline projected to have a net present value nearing CAD$1 billion, the drugs target unmet needs in glaucoma, kidney disease, and ARDS. QBIO anticipates substantial returns, with potential strategic deals expected in early 2023.

Q BioMed Inc. (OTCQB: QBIO) has updated shareholders focusing on monetizing its drug pipeline and growth strategies for 2022. The firm anticipates amending its agreement with Mannin Research to secure an equity stake, adding significant value to its assets. Mannin's drug program is progressing, with a clinical trial in ARDS expected in the next 8 months. The company is employing a roll-up strategy centered on rare diseases and has seen revenue from Strontium89 exceed 2021 figures. Although the stock's performance is disappointing, the firm believes its asset value is significantly undervalued.

Q BioMed Inc. has received a European Patent for the GDF15 biomarker, which can predict glaucoma disease progression. The biomarker allows for better treatment decisions by providing an objective measure, unlike current methods reliant on intraocular pressure and perimetry. GDF15, identified by Dr. Rajendra Apte, is critical for early detection and continuous monitoring of glaucoma, which affects over 100 million patients globally. The company aims to develop both diagnostic and therapeutic solutions in partnership with Mannin Research.

Q BioMed, Inc. (QBIO) announced the publication of preclinical research in Pharmaceuticals demonstrating that its chemotherapeutic agent Uttroside-B (Utt-B) shows superior efficacy and safety compared to sorafenib, the current FDA-approved treatment for hepatocellular carcinoma (HCC). The research, backed by FDA's orphan drug designation, indicates that Utt-B has a significantly lower toxicity profile and effectively reduces tumor growth in HCC models. The findings may pave the way for better treatment options for liver cancer patients in need.

Q BioMed Inc. outlines its strategic focus and value proposition to shareholders, emphasizing portfolio development in the biomedical sector. The company highlights its FDA-approved Strontium89 radiopharmaceutical, projecting revenue growth to $1M this year and $5-$7M by 2024. Additionally, the partnership with Mannin Research aims to accelerate ARDS therapeutics, tapping into a $50B market. Q BioMed plans to focus on rare diseases with potential acquisitions to strengthen its market position. However, the company expresses concern over its current market cap relative to its pipeline value.

Q BioMed, Inc. (OTCQB: QBIO) announced a new publication confirming the efficacy of its Uttroside B chemotherapeutic in treating liver cancer. The study shows Uttroside B is significantly more cytotoxic to liver cancer cells compared to sorafenib and induces tumor shrinkage in animal models. The compound has received patent protection in multiple countries and 'Orphan Drug' status from the U.S. FDA. The research indicates that combining Uttroside B with chloroquine can enhance its antitumor effects. CEO Denis Corin stated they are finalizing manufacturing for toxicity studies to move towards clinical trials.

On March 7, 2022, Q BioMed (OTCQB: QBIO) announced a confirmed order of $500,000 for Strontium Chloride USP Injections under a supply contract with isoSolutions and Chengdu Syncor Pharmaceutical Co. Ltd. This contract marks a significant entry into the Chinese radiopharmaceutical market, which is currently demanding 12,000 doses annually and growing at 10% per year. Q BioMed plans to commence shipments in April and continue through 2023. Strontium89 is FDA-approved for treating painful skeletal metastases.